Ordopidine

Drug Profile

Ordopidine

Alternative Names: ACR-325

Latest Information Update: 03 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Carlsson Research AB; NeuroSearch Sweden AB
  • Developer Saniona
  • Class Antidepressants; Antimanics; Fluorobenzenes; Piperidines; Sulfones
  • Mechanism of Action Adrenergic receptor modulators; Dopamine release modulators; Glutamate agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bipolar disorders; Parkinson's disease

Most Recent Events

  • 31 May 2016 Phase-I clinical trials in Bipolar disorders in Sweden (PO)
  • 31 May 2016 Phase-I clinical trials in Parkinson's disease in Germany (PO)
  • 31 May 2016 Phase-I clinical trials in Parkinson's disease in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top